This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Robert J. Cody, MD

Arch Intern Med. 1994;154(18):2029-2036.

Abstract
Angiotensin-converting enzyme inhibitors are proved, effective agents for the treatment of hypertension and congestive heart failure. New data suggest that angiotensinconverting enzyme inhibitors may be effective therapy for patients following acute myocardial infarction. Results from clinical trials, such as the Survival and Ventricular Enlargement trial, have demonstrated that captopril attenuates left ventricular enlargement, minimizes and/or prevents the subsequent development of overt congestive heart failure, and improves survival in patients with asymptomatic left ventricular dysfunction after myocardial infarction. Clinical reinfarctions and need for subsequent revascularization procedures were also reduced with captopril. In the Acute Infarction Ramipril Efficacy study, patients with clinically evident heart failure following acute myocardial infarction who received ramipril demonstrated a significant reduction in mortality and cardiovascular events. The mortality benefit in this study was evident within 30 days, possibly reflecting differences in patients studied (ie, population with highrisk heart failure in the Acute Infarction Ramipril Efficacy study as opposed to population with asymptomatic left ventricular dysfunction in the Survival and Ventricular Enlargement trial). Contrary results have been reported in another major postmyocardial infarction trial, the Cooperative New Scandinavian Enalapril Survival Study, which evaluated enalaprilat/enalapril maleate in unselected patients with acute myocardial infarction. This article reviews the recent trials using angiotensin-converting enzyme inhibition after myocardial infarction and will explore the reasons why angiotensin-converting enzyme inhibition seems to be beneficial in this clinical setting.

(Arch Intern Med. 1994;154:2029-2036)

Author Affiliations
From the Division of Cardiology, The Ohio State University Medical Center, Columbus.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Reversal of hypertension by angiotensin II type 1 receptor antisense gene therapy in the adult SHR
Katovich et al.
Am. J. Physiol. Heart Circ. Physiol. 1999;277:H1260-H1264.
ABSTRACT | FULL TEXT  

Effect of aspirin and ifetroban on skeletal muscle blood flow in patients with congestive heart failure treated with enalapril
Katz et al.
J Am Coll Cardiol 1999;34:170-176.
ABSTRACT | FULL TEXT  

A Congestive Heart Failure Project with Measured Improvements in Care
Delong et al.
Eval Health Prof 1998;21:472-486.
ABSTRACT  

Improvement of Alveolar–Capillary Membrane Diffusing Capacity With Enalapril in Chronic Heart Failure and Counteracting Effect of Aspirin
Guazzi et al.
Circulation 1997;95:1930-1936.
ABSTRACT | FULL TEXT  

Angiotensin II Receptor Inhibition: A New Therapeutic Principle
Messerli et al.
Arch Intern Med 1996;156:1957-1965.
ABSTRACT  

The Angiotensin II Type 1 Receptor Antagonists: A New Class of Antihypertensive Drugs
Bauer and Reams
Arch Intern Med 1995;155:1361-1368.
ABSTRACT  

ACE Inhibitors After Acute Myocardial Infarction
Cheng
Arch Intern Med 1995;155:645-645.
ABSTRACT